OTCMKTS:ALIOF ALIOF (ALIOF) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free ALIOF Stock Alerts $278.50 0.00 (0.00%) (As of 09/27/2022) Add Compare Share Share Today's Range$278.50▼$278.5050-Day Range$278.50▼$278.5052-Week Range$138.01▼$286.30VolumeN/AAverage Volume924 shsMarket Capitalization$29.89 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ALIOF alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About ALIOF Stock (OTCMKTS:ALIOF)Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.Read More ALIOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIOF Stock News HeadlinesAugust 24, 2023 | thestreet.com5 Things You Must Know Before the Market Opens FridayMay 5, 2023 | msn.comIndia goes Digital: 5 major indicators of MASSIVE transformationSee More Headlines Receive ALIOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALIOF and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/16/2015Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medicinals & Botanicals Sub-IndustryN/A Current SymbolOTCMKTS:ALIOF CUSIPN/A CIKN/A Webwww.actelion.com Phone(161) 565-6565Fax41-61-565-6500EmployeesN/AYear Founded1997Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares107,330,000Free FloatN/AMarket Cap$29.89 billion OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesNicholas FrancoChief Business Development Officer & EVPKey CompetitorsResMedNYSE:RMDWest Pharmaceutical ServicesNYSE:WSTBiogenNASDAQ:BIIBICON PublicNASDAQ:ICLRTerumoOTCMKTS:TRUMYView All Competitors Should I Buy ALIOF Stock? ALIOF Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in ALIOF: ALIOF is a pharmaceutical company that develops, produces, and markets drugs, which can provide stable revenue streams. Recent head-to-head survey comparisons with other companies like biote (NASDAQ: BTMD) indicate ALIOF's competitive positioning in the market. ALIOF's focus on research, development, and distribution of pharmaceutical products showcases a commitment to innovation and growth. Strong leadership team with founders who have a history of successful ventures in the pharmaceutical industry. Current stock price of ALIOF is showing positive momentum, indicating potential for capital appreciation. Cons Investors should be bearish about investing in ALIOF for these reasons: Market volatility in the pharmaceutical industry can impact ALIOF's stock price and financial performance. Regulatory challenges and changes in healthcare policies can affect the company's operations and profitability. Competition from other pharmaceutical companies may pose challenges to ALIOF's market share and growth prospects. Dependency on successful research and development outcomes for new products, which can be uncertain and costly. Economic conditions and global health events can influence demand for pharmaceutical products, impacting ALIOF's revenue streams. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, March 26, 2024. Please send any questions or comments about these ALIOF pros and cons to contact@marketbeat.com. ALIOF Stock Analysis - Frequently Asked Questions How have ALIOF shares performed in 2024? ALIOF's stock was trading at $278.50 at the beginning of the year. Since then, ALIOF shares have increased by 0.0% and is now trading at $278.50. View the best growth stocks for 2024 here. How were ALIOF's earnings last quarter? ALIOF (OTCMKTS:ALIOF) released its quarterly earnings results on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $1.09 by $0.22. The company had revenue of $501.50 million for the quarter, compared to analysts' expectations of $546.30 million. How do I buy shares of ALIOF? Shares of ALIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ALIOF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALIOF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.